专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明申请

US20030087956A1 Urea compounds as inhibitors for vla-4 审中-公开
标题翻译：尿素化合物作为vla-4的抑制剂
公开(公告)号：US20030087956A1
公开(公告)日：2003-05-08
申请号：US10149932
申请日：2002-06-14
发明人： Craig Johnstone , Michael Stewart Large
IPC分类号： A61K031/36 , A61K031/277 , A61K031/195 , A61K031/24 , A61K031/165
CPC分类号： C07D295/088 , C07C275/42 , C07C317/18 , C07C323/12 , C07C2601/08 , C07D211/22 , C07D211/54
摘要： 1 A compound of formula (I) where D is a VLA-4 specificity determinant which does not impart significant IIB/IIIa activity; R41 is a group of the formula (V): U - (CH2)d - V - T wherein U is selected from oxygen, sulphur, a direct bond or nullCH2Onull, V is selected from nitrogen, oxygen, sulphur, S(O), S(O)2 or a direct bond, d is zero or a number from 1 to 4, and T is selected from a range of variables defined in the application; and other variables are defined in the application, or a pharmaceutically acceptable salt or in vivo hydrolysable derivative thereof. The compounds are useful in the treatment of disease mediated by the interaction between VCAM-1 and/or fibronectin and the integrin receptor null4null1. Pharmaceutical compositions and methods of use or treatment are also described and claimed.
摘要翻译：式（I）的化合物，其中D是不赋予显着IIB / IIIa活性的VLA-4特异性决定簇; R41是式（Ⅴ）的基团：U-（CH2）d-V-T其中U选自氧，硫，直接键或-CH 2 O-，V选自氮，氧，硫，S（ O），S（O）2或直接键合，d为0或1至4的数，T选自本申请中定义的变量范围; 和其它变量在本申请中定义，或其药学上可接受的盐或体内可水解的衍生物。该化合物可用于治疗由VCAM-1和/或纤连蛋白与整联蛋白受体α4β1相互作用介导的疾病。也描述和要求保护药物组合物和使用或治疗方法

52. 发明申请

US20030072789A1 Wipe formulation 有权
标题翻译：擦拭配方
公开(公告)号：US20030072789A1
公开(公告)日：2003-04-17
申请号：US09968200
申请日：2001-10-01
申请人： Playtex Products, Inc.
发明人： Catherine Durden
IPC分类号： A61K031/56 , A61K031/46 , A61K009/70 , A61K031/045 , A61K031/24
CPC分类号： A61Q19/00 , A61K8/0208 , A61K8/365 , A61K8/97 , A61K9/0034 , A61K2800/75 , Y10S514/817 , Y10S514/828 , Y10S514/887 , Y10S514/947 , Y10S514/967
摘要： The present invention relates to a liquid formulation for a feminine wipe. The preferred formulation has an anti-irritant agent, a pH adjuster namely citric acid, and at least one preservative.
摘要翻译：本发明涉及一种用于女性擦拭物的液体制剂。优选的制剂具有抗刺激剂，pH调节剂，即柠檬酸，和至少一种防腐剂。

53. 发明申请

US20030021754A1 Delivery of anti-migraine compounds through an inhalation route 失效
标题翻译：通过吸入途径输送抗偏头痛化合物
公开(公告)号：US20030021754A1
公开(公告)日：2003-01-30
申请号：US10152640
申请日：2002-05-20
发明人： Joshua D. Rabinowitz , Alejandro C. Zaffaroni
IPC分类号： A61K009/14 , A61K031/554 , A61K031/553 , A61K031/24
CPC分类号： A61K9/007 , A61K9/0073 , A61K9/12 , A61K31/00 , A61K31/137 , A61K31/138 , A61K31/165 , A61K31/19 , A61K31/192 , A61K31/195 , A61K31/216 , A61K31/27 , A61K31/404 , A61K31/405 , A61K31/407 , A61K31/4196 , A61K31/421 , A61K31/422 , A61K31/423 , A61K31/437 , A61K31/473 , A61K31/485 , A61K31/49 , A61K31/495 , A61K31/496 , A61K31/4985 , A61K31/501 , A61K31/519 , A61K31/53 , A61K31/551 , A61K31/5517 , A61K47/54 , A61M11/042 , A61M15/06 , A61M2205/8206 , F24V30/00 , Y10S514/923 , Y10S514/958
摘要： The present invention relates to the delivery of anti-migraine compounds through an inhalation route. Specifically, it relates to aerosols containing lidocaine, verapamil, diltiazem, isometheptene, or lisuride that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of lidocaine, verapamil, diltiazem, isometheptene, or lisuride. In a method aspect of the present invention, one of lidocaine, verapamil, diltiazem, isometheptene, or lisuride is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of lidocaine, verapamil, diltiazem, isometheptene, or lisuride, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering lidocaine, verapamil, diltiazem, isometheptene, or lisuride through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of lidocaine, verapamil, diltiazem, isometheptene, or lisuride; and, b) a device that forms a lidocaine, verapamil, diltiazem, isometheptene, or lisuride containing aerosol from the composition, for inhalation by the mammal.
摘要翻译：本发明涉及通过吸入途径递送抗偏头痛化合物。具体地说，它涉及在吸入治疗中使用的含有利多卡因，维拉帕米，地尔硫卓，异月精或伊瑞沙德的气溶胶。在本发明的组合物方面，所述气雾剂包含包含至少5重量％的利多卡因，维拉帕米，地尔硫卓，异月桂烯或碘化尿素的颗粒。在本发明的方法方面，通过吸入途径将利多卡因，维拉帕米，地尔硫卓，异月精或伊瑞沙肽中的一种递送至哺乳动物。所述方法包括：a）加热组合物，其中所述组合物包含至少5重量％的利多卡因，维拉帕米，地尔硫卓，异月桂烯或碘化尿，以形成蒸气; 和b）允许蒸气冷却，由此形成包含由哺乳动物吸入的颗粒的冷凝气雾剂。在本发明的试剂盒方面，提供了一种用于通过吸入途径将哺乳动物输送利多卡因，维拉帕米，地尔硫卓，异月桂烯或伊瑞沙丁的试剂盒，其包括：a）包含至少5重量％的利多卡因，维拉帕米，地尔硫卓，异月桂烯或碘化;; 和b）一种从哺乳动物吸入形成利多卡因，维拉帕米，地尔硫卓，异月桂烯或含有来自该组合物的气溶胶的装置。

54. 发明申请

US20030018073A1 Reagents and method for spatio-temporal control of gene expression by illumination 失效
标题翻译：通过照明进行基因表达的空间 - 时间控制的试剂和方法
公开(公告)号：US20030018073A1
公开(公告)日：2003-01-23
申请号：US10078339
申请日：2002-02-21
发明人： Joseph Pao Yung Kao , David Ari Freilich
IPC分类号： A61K031/24 , A01N037/12 , C07C235/78
CPC分类号： A61K31/221 , A61K31/195 , A61K31/216 , C07C243/38
摘要： A caged non-steroidal ecdysome memetic (NSE) compound and a method for producing free NSE by subjecting the charged NSE to UV irradiation.
摘要翻译：笼状非甾体ecdysome模型（NSE）化合物和通过使带电的NSE经受UV照射来产生游离NSE的方法。

55. 发明申请

US20020193422A1 Anthranilamides and methods of their use 审中-公开
标题翻译：邻氨基苯甲酰胺及其使用方法
公开(公告)号：US20020193422A1
公开(公告)日：2002-12-19
申请号：US10132184
申请日：2002-04-26
发明人： Joachim Brendel , Bernard Pirard
IPC分类号： A61K031/381 , A61K031/277 , A61K031/343 , A61K031/24 , A61K031/18 , A61K031/195
CPC分类号： A61K31/18 , A61K31/341 , A61K31/381
摘要： The presently disclosed invention relates to compounds of general formula I: 1 and/or any pharmaceutically acceptable salts thereof. The present invention discloses methods of preparing such compounds, and their use as medicaments having a Knull-channel-blocking activity to treat and/or prevent Knull-channel-mediated diseases, such as cardiac arrhythmias, reentry arrhythmias, supraventricular arrhythmias, atrial fibrillation or atrial flutter.
摘要翻译：本发明公开的发明涉及通式I的化合物：和/或其任何药学上可接受的盐。本发明公开了制备这些化合物的方法及其作为具有K +通道阻断活性的药物用于治疗和/或预防K +通道介导的疾病如心律失常，再入心律失常，室上性心律失常，房颤或心房扑动

56. 发明申请

US20020183391A1 Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives 失效
标题翻译：某些5-烷基-2-芳基氨基苯基乙酸及其衍生物
公开(公告)号：US20020183391A1
公开(公告)日：2002-12-05
申请号：US10201336
申请日：2002-07-23
发明人： Roger A. Fujimoto , Leslie W. McQuire , Benjamin B. Mugrage , John H. Van Duzer , Daqiang Xu
IPC分类号： A61K031/24 , A61K031/195
CPC分类号： C07C229/42
摘要： Disclosed are the compounds of formula I 1 wherein R is methyl or ethyl; R1 is chloro or fluoro; R2 is hydrogen or fluoro; R3 is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy; R4 is hydrogen or fluoro; and R5 is chloro, fluoro, trifluoromethyl or methyl; and pharmaceutically acceptable salts thereof, as selective COX-2 cyclooxygenase inhibitors; and pharmaceutically acceptable prodrug esters thereof.
摘要翻译：公开了式I的化合物，其中R是甲基或乙基; R1是氯或氟; R2是氢或氟; R3是氢，氟，氯，甲基，乙基，甲氧基，乙氧基或羟基; R4是氢或氟; R5是氯，氟，三氟甲基或甲基; 作为选择性COX-2环加氧酶抑制剂; 及其药学上可接受的前药酯。

57. 发明申请

US20020183356A1 Local anesthetic methods and kits 有权
标题翻译：局部麻醉方法和试剂盒
公开(公告)号：US20020183356A1
公开(公告)日：2002-12-05
申请号：US10155171
申请日：2002-05-28
申请人： Novalar Pharmaceuticals, Inc.
发明人： Eckard Weber , Howard I Katz
IPC分类号： A61K031/24 , A61K031/137
CPC分类号： A61K31/135 , A61K31/165 , A61K31/24 , A61K31/415 , A61K31/44 , A61K31/445 , A61K31/505 , Y10S435/81 , Y10S514/816 , Y10S514/818
摘要： Methods of reversing local anesthesia are disclosed. The methods comprise administering a local anesthetic and alpha adrenergic receptor agonist to induce local anesthesia followed by reversing anesthesia with a low dose of an alpha adrenergic receptor antagonist. Also disclosed are kits comprising a local anesthetic, an alpha adrenergic receptor agonist and a low dose of an alpha adrenergic receptor antagonist.
摘要翻译：公开了逆转局部麻醉的方法。所述方法包括施用局部麻醉剂和α肾上腺素能受体激动剂以诱导局部麻醉，然后用低剂量的α肾上腺素能受体拮抗剂逆转麻醉。还公开了包含局部麻醉剂，α肾上腺素能受体激动剂和低剂量α肾上腺素能受体拮抗剂的试剂盒。

58. 发明申请

US20020165275A1 Trisubstituted carbocyclic cyclophilin binding compounds and their use 失效
标题翻译：三取代碳环亲环蛋白结合化合物及其用途
公开(公告)号：US20020165275A1
公开(公告)日：2002-11-07
申请号：US10057203
申请日：2002-01-25
发明人： Yong-Qian Wu , Sergei Belyakov , Gregory S. Hamilton , David Limburg , Joseph P. Steiner , Mark Vaal , Ling Wei , Douglas Wilkinson
IPC分类号： A61K031/255 , A61K031/24 , A61K031/18 , A61K031/17 , A61K031/16
CPC分类号： C07D209/48 , A61K31/325 , C07C233/29 , C07C233/66 , C07C233/75 , C07C233/76 , C07C235/42 , C07C235/56 , C07C243/38 , C07C255/54 , C07C275/42 , C07C311/46 , C07C311/48 , C07C335/18 , C07C335/36 , C07C337/06 , C07C2602/10 , C07D213/56 , C07D213/74 , C07D231/12 , C07D233/56 , C07D249/08 , C07D295/135 , Y02A50/409 , Y02A50/411 , Y02A50/421 , Y02A50/422 , Y02A50/423
摘要： The present invention relates to novel, non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilin proteins, and to pharmaceutical compositions comprising one or more of the said compounds. The invention further relates to the uses of these compounds and compositions for binding CyP-type proteins, inhibiting their peptidyl-prolyl isomerase activity, and for research, development, and therapeutic applications in a variety of medical disorders.
摘要翻译：本发明涉及对亲环蛋白（CyP）型免疫亲和素蛋白具有亲和力的新颖的非肽小有机化合物，以及包含一种或多种所述化合物的药物组合物。本发明还涉及这些化合物和组合物用于结合CyP型蛋白质，抑制其肽基 - 脯氨酰异构酶活性以及用于各种医学疾病的研究，开发和治疗应用的用途。

59. 发明申请

US20020151586A1 Acylphenylurea derivatives, a process for their preparation and their use as pharmaceuticals 有权
标题翻译：酰基苯基脲衍生物，其制备方法及其作为药物的用途
公开(公告)号：US20020151586A1
公开(公告)日：2002-10-17
申请号：US09875901
申请日：2001-06-08
发明人： Elisabeth Defossa , Thomas Klabunde , Hans-Joerg Burger , Andreas Herling , Karl-Heinz Baringhaus
IPC分类号： A61K031/277 , A61K031/24 , A61K031/17 , A61K031/18 , A61K031/196
CPC分类号： C07D295/088 , A61K31/17 , A61K45/06 , C07C275/54 , C07D307/38 , A61K2300/00
摘要： The invention is directed to acylphenylurea derivatives and their physiologically tolerated salts and physiologically functional derivatives. Compounds of the formula I 1 in which the radicals have the stated meanings, and their physiologically tolerated salts and a process for their preparation are described. The compounds are suitable, for example, for treating type 11 diabetes.
摘要翻译：本发明涉及酰基苯基脲衍生物及其生理上耐受的盐和生理功能衍生物。描述了其中基团具有所述含义的式I化合物及其生理上耐受的盐及其制备方法。该化合物适用于例如用于治疗11型糖尿病。

60. 发明申请

US20020065266A1 Use of ion channel modulating agents 失效
标题翻译：使用离子通道调节剂
公开(公告)号：US20020065266A1
公开(公告)日：2002-05-30
申请号：US09984061
申请日：2001-10-25
发明人： Bo Skaaning Jensen , Lene Teuber , Dorte Strobaek , Palle Christophersen , Soren Peter Olesen
IPC分类号： A61K031/55 , A61K031/473 , A61K031/47 , A61K031/24 , A61K031/21 , A61K031/15
CPC分类号： A61K45/06 , A61K31/122 , A61K31/15 , A61K31/403 , A61K31/404 , A61K31/4045 , A61K31/55 , Y02A50/409
摘要： The present invention relates to the use of a particular class of chemical compounds as modulators of SKCa, IKCa and BKCa channels, and to pharmaceutical compositions comprising the SK/IK/BK channel modulating agents.
摘要翻译：本发明涉及特定类别的化合物作为SKCa，IKCa和BKCa通道的调节剂的用途，以及包含SK / IK / BK通道调节剂的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式